Ocugen, Inc. (OCGN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Malvern, PA, United States. The current CEO is Shankar Musunuri.
OCGN has IPO date of 2014-12-03, 95 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $590.21M.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
